| Literature DB >> 36056998 |
Anjuly Castelan1,2, Jeannine F Nellen2, Marc van der Valk2, Pythia T Nieuwkerk3.
Abstract
Medication non-adherence can be intentional or unintentional. We investigated the prevalence of unintentional and intentional non-adherence to antiretroviral therapy (ART) and the relationship with beliefs about medicines, sociodemographic- and HIV-related variables among people with HIV (PWH) attending the HIV clinic of the Amsterdam University Medical Centers. Participants completed the Medication Adherence Rating Scale (MARS) and the Beliefs about Medicines (BMQ) questionnaire. About half of 80 participants reported unintentional non-adherence and 20% reported intentional non-adherence. Both unintentional and intentional non-adherence were associated with younger age. Additionally, intentional non-adherence was associated with being a migrant from Suriname /Netherlands Antilles, having more concerns about negative effects of ART and stronger beliefs that medicines in general are overused/ overprescribed. In conclusion, intentional but not unintentional non-adherence was associated with beliefs about medicines. Eliciting and discussing beliefs about medicines may be a promising avenue to address patients' concerns and perceptions thereby potentially enhancing medication adherence.Entities:
Keywords: Beliefs about medicines; Combination antiretroviral therapy; HIV/AIDS; Intentional medication non-adherence; Unintentional medication non-adherence
Year: 2022 PMID: 36056998 PMCID: PMC9440648 DOI: 10.1007/s10461-022-03842-y
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Characteristics of study participants
| Total sample | |
|---|---|
|
| |
| Age (years), mean (SD) | 52 (12) |
| Male gender, % ( | 64% (51/80) |
| Region/ country of origin1 | |
| Netherlands | 44% (35/80) |
| Africa | 24% (19/80) |
| Suriname and Netherlands Antilles | 11% ( 9/80) |
| Europe | 13% (10/80) |
| Other | 8% (6/80 ) |
| Plasma HIV RNA concentration2 | |
| < 50 copies/mL | 95% (74/78) |
| 50 to 100 copies/mL | 1.3% (1/78) |
| 100 to 1000 copies/mL | 2.5% (2/78) |
| > 1000 copies/mL | 1.3% (1/78) |
| Most recent CD4-cell count (cells/mm3), median (IQR) | 680 (533 to 880) |
| Number of prescribed HIV-medications | |
| 1 | 56% (45/80) |
| > 1 | 44% (35/80) |
| HIV medication daily dosing frequency | |
| 1 | 85% (68/80) |
| > 1 | 15% (12/80) |
| Number of co-medications | |
| 0 | 36% (29/80) |
| 1 | 18% (14/80) |
| > 1 | 46% (37/80) |
| Years since HIV diagnosis, median (IQR) | 17 (11 to 23) |
| Years since ART, median (IQR) | 15 (9 to 21) |
SD = standard deviation, IQR = interquartile range, 1 = one person did not want to disclose his/her region/ country of origin, 2 = missing for 2 persons
Factors associated with unintentional and intentional non-adherence
| Unintentional non-adherence (versus full adherence) | Intentional non-adherence (versus full adherence) | |||
|---|---|---|---|---|
| Odds ratio (95% confidence interval) | p- value | Odds ratio (95% confidence interval) | p-value | |
| Age, years | 0.94 (0.89, 0.99) | 0.02 | 0.92 (0.86 to 0.99) | 0.02 |
| Male gender | Reference | Reference | ||
| Female gender | 1.10 (0.39 to 3.13) | 0.86 | 1.13 (0.31 to 4.14) | 0.85 |
|
| ||||
| Netherlands | Reference | Reference | ||
| Africa | 0.96 (0.27 to 3.45) | 0.95 | 2.71 (0.53 to 13.86) | 0.23 |
| Suriname and Netherlands Antilles | 0.36 (0.03 to 4.42) | 0.43 | 9.75 (1.38 to 68.78) | 0.02 |
| Europe | 0.90 (0.20 to 4.03) | 0.89 | 0.81 (0.07 to 9.52) | 0.87 |
| Other | 3.61 (0.38 to 34.69) | 0.27 | * | 1.00 |
| No/minor language barrier | Reference | Reference | ||
| Major language barrier | 0.19 (0.03 to 1.01) | 0.051 | 0.48 (0.08 to 2.71) | 0.40 |
| Most recent CD4-cell count | 0.44 (0.07 to 2.82) | 0.38 | 0.20 (0.01 to 3.03) | 0.25 |
|
| ||||
| 1 | Reference | Reference | ||
| > 1 | 2.20 (0.79 to 6.10) | 0.13 | 0.37 (0.08 to 1.63) | 0.19 |
|
| ||||
| 1 | Reference | Reference | ||
| > 1 | 0.58 (0.14, to 2.48) | 0.46 | 0.91 (0.14 to 6.16) | 0.93 |
|
| Reference | Reference | ||
| 1 | 0.93 (0.21 to 4.18) | 0.93 | 1.00 (0.16 to 6.26) | 1.00 |
| > 1 | 0.61 (0.20 to 1.87) | 0.39 | 0.68 (0.17 to 2.69) | 0.57 |
|
| 1.02 (0.97 to 1.08) | 0.42 | 0.99 (0.92 to 1.06) | 0.76 |
|
| 1.00 (0.94 to 1.06) | 0.98 | 0.97 (0.90 to 1.05) | 0.46 |
|
| ||||
| Necessity | 1.03 (0.91 to 1.18) | 0.61 | 0.89 (0.76 to 1.06) | 0.19 |
| Concerns | 1.05 (0.94 to 1.18) | 0.40 | 1.21 (1.04 to 1.41) | 0.01 |
| Overuse | 1.09 (0.89 to 1.35) | 0.40 | 1.32 (1.00 to 1.74) | 0.05 |
| Harm | 1.12 (0.91 to 1.36) | 0.28 | 1.24 (0.99 to 1.55) | 0.06 |
|
| ||||
| Worsening of adherence | * | 1.60 (1.10 to 2.34) | 0.002 | |
| More difficult to obtain HIV medicines | 3.04 (0.26 to 35.5) | 0.72 | 0.48 (0.06 to 3.86) | 0.60 |
| More difficult to receive medical care | 1.07 (0.31 to 3.73) | 1.00 | 1.33 (0.30 to 5.96) | 0.72 |
*Odds ratio could not be calculated due to empty cells/categories

Fig. 1